Objective: To validate WINROP, a web-based screening tool for retinopathy of prematurity (ROP), in the detection of any-stage ROP or treatment-requiring ROP among Filipino preterm infants screened for ROP from January 2013 to April 2017. Methods: Charts of preterm infants who were screened for ROP at a tertiary hospital from January 2013 to April 2017 were reviewed. Birth date, gestational age, birth weight, and weekly postnatal weight measurements were collected and entered into WINROP. The number of infants that were tagged by WINROP with alarm signals for any-stage ROP or treatment-requiring ROP were noted and compared with actual ROP screening findings. The sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV) of the WINROP application in predicting any-stage ROP and treatment-requiring ROP were computed. Results: Charts of 138 preterm infants were included in the study. Sixty-four (64) had a chart diagnosis of anystage ROP and 13 had treatment-requiring ROP. WINROP tagged 77 and 10 preterm infants with any-stage ROP and treatment-requiring ROP, respectively. The sensitivity and specificity rates of WINROP for detecting any-stage ROP were 63.5% (95% CI: 51.5% - 74.2%) and 78.1% (95% CI: 65.7% - 87.1%), respectively. While the sensitivity and specificity rates at identifying treatment-requiring ROP were 76.9% (95% CI: 45.9% - 93.8%) and 46.4% (95% CI: 37.5% - 55.5%), respectively. Conclusion WINROP is fairly sensitive and specific in predicting any-stage ROP but has fair sensitivity and poor specificity in predicting treatment-requiring ROP. WINROP may aid in ROP prediction, but regular screening of preterm infants at risk for ROP based on current criteria remains to be the standard of care.
Retinopathy of Prematurity

Objective: To determine the outcomes of retinopathy of prematurity (ROP) screening at a tertiary government hospital. Method: Medical records of premature infants who underwent ROP screening at a tertiary government hospital from January 2008 to July 2012 were obtained. Eventual outcomes of the ROP screening were collated and analyzed. Results: A total of 194 premature infants (388 eyes) were included in the study. Forty six (23.71%) infants developed some form of ROP of which 41 (90.21%) had bilateral disease. Of the 388 eyes, 92 (23.71%) were diagnosed with ROP. Thirty-five eyes (38.08%) with ROP were classified as stage 2, 23 (25.00%) stage 1, and 13 (14.13%) stage 3. Twelve eyes (13.04%) diagnosed with ROP received treatment that included laser therapy in 4 eyes (33.33%), intravitreal bevacizumab injection in 4 eyes (33.33%), cryotherapy in one eye (8.33%), and laser therapy plus intravitreal bevacizumab injection in 3 eyes (25%). Seven eyes (7.60%) required treatment but parents did not comply. Sixteen patients (10.81%) without ROP and 27 patients (57.61%) with ROP had follow-up examinations. Of the 54 eyes with ROP that were followed up, only 26 eyes had refraction. Twelve eyes (46.15%) were hyperopic, 12 (46.15%) myopic, and two (7.69%) emmetropic. Among 16 eyes without ROP with follow-up examination, 14 eyes (87.50%) had hyperopia and two (12.50%) myopia. The follow-up rate for this study was 22.16%. Conclusion There was a low follow-up rate for premature babies screened for ROP at a tertiary government center. No association was found between presence of ROP and refractive outcomes, and between refractive outcomes and treatment received.
Retinopathy of Prematurity ; Prevalence